ArrowMark Colorado Holdings LLC Purchases 337,026 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

ArrowMark Colorado Holdings LLC grew its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 14.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,723,715 shares of the medical device company's stock after acquiring an additional 337,026 shares during the period. Tandem Diabetes Care accounts for 1.3% of ArrowMark Colorado Holdings LLC's portfolio, making the stock its 23rd largest holding. ArrowMark Colorado Holdings LLC owned about 4.15% of Tandem Diabetes Care worth $98,108,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Hood River Capital Management LLC acquired a new position in Tandem Diabetes Care during the 4th quarter worth $46,035,000. Park West Asset Management LLC lifted its stake in shares of Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after acquiring an additional 530,000 shares during the period. Baillie Gifford & Co. increased its position in Tandem Diabetes Care by 235.7% in the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after purchasing an additional 523,843 shares during the period. GW&K Investment Management LLC raised its holdings in Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its position in Tandem Diabetes Care by 22.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock valued at $56,040,000 after purchasing an additional 281,327 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have commented on TNDM shares. Mizuho began coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price for the company. Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the company from $35.00 to $25.00 in a research note on Friday, February 28th. Stifel Nicolaus decreased their target price on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research report on Thursday. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada decreased their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $39.81.

Tandem Diabetes Care Stock Up 7.5 %

TNDM stock opened at $21.48 on Friday. The firm has a market capitalization of $1.43 billion, a PE ratio of -11.13 and a beta of 1.52. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The stock's 50 day moving average is $18.80 and its 200-day moving average is $28.63.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. During the same quarter last year, the business posted ($0.65) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. Sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.90% of the stock is owned by insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.